Primary source Biotechnology and Bioengineering: Increasing Adenovirus Upstream Process Productivity Using a High Cell Density Perfusion Strategy

A paper published online on 18 November 2026 in Biotechnology and Bioengineering reports an upstream process for adenovirus vectors that reaches 3 x 10^12 virus particles per mL of culture. The authors are affiliated with Sartorius Stedim Biotech (Goettingen, Germany) and the Jenner Institute at the University of Oxford. This note is based on the abstract only. The full text was not available to us.
What the authors report
The process combines perfusion cell culture (fresh medium is fed continuously while spent medium is removed and cells are retained) with a highly productive cell line capable of vector transgene repression. The abstract says the process uses only commercially accessible materials.
The authors used a multi-parallel scale-down perfusion bioreactor system to select straightforward perfusion conditions, both for expanding uninfected cells and for virus production. According to the abstract, this maintains high cell-specific productivity (virus produced per cell) at cell densities up to 40 x 10^6 cells per mL. Cell density is a known limit here, since productivity per cell often falls as density rises.
The authors write that they believe this may be the highest productivity yet reported for an adenovirus platform, including previous reports that used proprietary cell lines. That is the authors’ own belief, not a result we could check.
Why the authors say it matters
The abstract notes that large-scale production of adenovirus-vectored COVID-19 vaccines showed the value of platform manufacturing, but that vaccine scarcity remained a problem in 2021. It calls for widely accessible, higher-yielding platform processes. The authors suggest the process could help both large-scale production and smaller facilities making products for niche indications or stockpiles.
What the abstract does not say
The abstract does not give bioreactor volumes beyond the scale-down system, infectivity or quality data, downstream recovery, or any run at manufacturing scale. It does not say how the yield compares numerically with a fed-batch or earlier perfusion process.
Sources
- Biotechnology and Bioengineering, Increasing Adenovirus Upstream Process Productivity Using a High Cell Density Perfusion Strategy, 18 Nov 2026 (abstract read via Europe PMC and Crossref).


